跳至主要内容
临床试验/CTRI/2019/02/017549
CTRI/2019/02/017549已完成未知

CB-NAAT, Its clinical utility in diagnosing cases of cutaneous tuberculosis and assessing rifampicin resistance.

King Georges Medical University0 个研究点目标入组 44 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
44

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • (a) Patients clinically diagnosed as cutaneous TB and who give consent to participate in

排除标准

  • (a) Who have taken ATT in last one year
  • (b) Contra-indication for biopsy or FNAC like bleeding and clotting disorders
  • (c) Patients with severe debilitating and chronic illness like Hepatitis B,C, malignancy,
  • uncontrolled diabetes etc
  • (d) Not willing to participate in study

研究者

发起方
King Georges Medical University

相似试验